Pushing the boundaries of Alzheimer’s disease research

Quanterix’s assays, complemented by the expertise of its Accelerator Lab, empower researchers to extend the frontiers of Alzheimer’s disease research.

By utilizing Quanterix, researchers unlock the potential for groundbreaking discoveries and contribute to the ongoing battle against neurodegenerative diseases with unparalleled precision and confidence. Opting for Quanterix means joining a collaborative effort to redefine Alzheimer’s research, ultimately paving the way for a brighter future.

Convenient assay kit option

The Simoa® ALZpath p-Tau 217 Advantage PLUS assay kit (104570) is designed for seamless implementation and precise p-Tau 217 quantification on the HD-X™. The user-friendly protocols allow researchers of all levels to set up an easy and simplified assay in their labs.

Robust and quantitative p-Tau 217 measurements provide comprehensive data to drive impactful research outcomes.

Pricing for p-Tau 217 research

The Quanterix team is committed to providing the most relevant and tailored pricing options to meet your specific needs. Detailed pricing information regarding the ALZpath p-Tau 217 Advantage PLUS assay is available from a dedicated Quanterix representative.

Source: Quanterix

. .
Assay Platform Quanterix Simoa®
Instrument HD-X Analyzer
General Description 2-step digital enzyme immunoassay
Automation Fully automated
Assay Timing 60-5 min
Capture Antibody Rabbit monoclonal IgG: p-Tau 217
Detector Antibody Mouse monoclonal IgG1 to the N-terminus of tau (441)
Calibrator Material Synthetic peptide
Dynamic Range 0.007-30.0 pg/mL
Calibrator Points # 7 + blank
Calibrator Fitting 1/y^2 weighted 5PL
Signal Enzyme/Substrate Streptavidin-b-galactosidase (SBG)
Substrate Resorufin-β-D-galacto pyranoside
Sample Type Human plasma (EDTA)
Sample Volume 100 μL for duplicate testing (on-board)
Sample Dilution 3x
Limit of Detection 0.021pg/mL1 (corrected for dilution)
Limit of Quantification 0.060 pg/mL1 (corrected for dilution)
Intra-Run Precision (%CV) 2.8-6.8% (plasma, 2 runs, 40 reps)1
Inter-Run Precision (%CV) 14.9-20.3% (3 plasma spms, 20 days)1
Parallelism Up to 8-fold dilution1
Clinical Accuracy CI A+T+ AUC 0.912,3,4
Clinical accuracy CU Ab AUC 0.842,3,4

Citations
1. QTRX fit-for-purpose validation report
2. Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. Published online January 22, 2024. doi:10.1001/jamaneurol.2023.5319
3. Brum WS, Ashton NJ, Simrén J, et al. Biological variation estimates of Alzheimer‘s disease plasma biomarkers in healthy individuals. Alzheimers Dement. Published online November 20, 2023. doi:10.1002/alz.13518
4. Xiao Z, Wu W, Ma X, et al. Plasma p-tau217, p-tau181, and NfL as early indicators of dementia risk in a community cohort: The Shanghai Aging Study. Alzheimers Dement (Amst). 2023;15(4):e12514. Published 2023 Dec 22. doi:10.1002/dad2.12514

About Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. Quanterix’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods.

Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,500 peer-reviewed journals.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jun 7, 2024 at 2:03 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Quanterix. (2024, June 07). Pushing the boundaries of Alzheimer’s disease research. News-Medical. Retrieved on October 13, 2024 from https://www.news-medical.net/whitepaper/20240604/Pushing-the-boundaries-of-Alzheimere28099s-disease-research.aspx.

  • MLA

    Quanterix. "Pushing the boundaries of Alzheimer’s disease research". News-Medical. 13 October 2024. <https://www.news-medical.net/whitepaper/20240604/Pushing-the-boundaries-of-Alzheimere28099s-disease-research.aspx>.

  • Chicago

    Quanterix. "Pushing the boundaries of Alzheimer’s disease research". News-Medical. https://www.news-medical.net/whitepaper/20240604/Pushing-the-boundaries-of-Alzheimere28099s-disease-research.aspx. (accessed October 13, 2024).

  • Harvard

    Quanterix. 2024. Pushing the boundaries of Alzheimer’s disease research. News-Medical, viewed 13 October 2024, https://www.news-medical.net/whitepaper/20240604/Pushing-the-boundaries-of-Alzheimere28099s-disease-research.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.